Register for our free email digests:
Regulation/Legislation (Wellness)
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
FDA Asks Whether Supplement Industry Has Outgrown Regulatory Framework
Commissioner Gottlieb appointed working group at FDA to evaluate agency's existing structure and strategies for oversight of supplement sector. Group's findings will determine extent of potential changes in regulatory authorities agency will ask members of Congress to establish through legislation. Action plan expected in early 2019.
Recruitment Begins For UK Health Claims Committee In Preparation For Brexit
Regulation
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Wellness & Regulation
Dietary Supplement Firms' Sun Protection Claims Scorched In NAD Review
National Advertising Division advises firms marketing supplements with claims to protect skin from sun rays to discontinue statements similar to claims made by four supplement firms FDA warned in May. Novahue and Dermatology Industry both disagreed with NAD but would comply with its recommendations.
TummyZen Firm Appeals After Heartburn Claims Don't Settle Well In NAD Review
Eli Consumer Healthcare is latest supplement marketer National Advertising Division has advised that tests of separate ingredients do not support claims for a whole product. Following NADs review of TummyZen claims on challenge by Tums firm GlaxoSmithKline, Eli Consumer appeals NAD's recommendations to discontinue claims that its supplement “stops acid production,” is “acid inhibiting,” “halts the secretion of chloride ions in your parietal cells to regulate the release of acid into your stomach,” “supports stomach lining” and is “long lasting."
UK To Overhaul Health Claims Approval In Event of 'No Deal' Brexit
In the event of a no deal Brexit, new health claims approved by EFSA will not be valid in the UK. Firms will need to seek approval from the new UKNHCC body.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.